Compare The Effect Of Tila Taila and Karpasasthyadi Taila As a Nasya Karma In The Management of Manyastambha (Cervical Spondylosis)
Phase 3
- Conditions
- Health Condition 1: M472- Other spondylosis with radiculopathy
- Registration Number
- CTRI/2023/09/057668
- Lead Sponsor
- Dr Biplab Keshari Jena
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patient fit for Nasya Karma.
Patients having sign and symptoms of Manyastambha (Cervical Spondylosis)
Exclusion Criteria
Patients with injury to cervical spine and spinal surgery.
Patients diagnosed with infection and neoplastic condition of spine.
Patient unfit for Nasya Karma.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To reduce the sign and symptoms of Manyastambha (Cervical Spondylosis) by using NECK DISABILITY INDEX Scale & Improve Range of movements of Cervical Spine- using a goniometer.Timepoint: Patients from both the groups will be assessed after 15 days.
- Secondary Outcome Measures
Name Time Method ILTimepoint: NI
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Tila Taila's efficacy in cervical spondylosis compared to Karpasasthyadi Taila?
How does Tila Taila Nasya compare to standard-of-care treatments for M472 cervical spondylosis in clinical outcomes?
Are there specific biomarkers that predict differential response to Tila Taila versus Karpasasthyadi Taila in cervical spondylosis?
What adverse events are associated with Tila Taila Nasya therapy in phase III trials for cervical spine disorders?
What combination therapies or alternative Ayurvedic formulations show promise in managing cervical spondylosis with radiculopathy?